已关闭
  • 文献求助详情
标题
Real life targeted therapies alone or in combination in brain metastases patients: French experience within MelBase
网址
求助人暂未提供
DOI
暂未提供,该求助的时间将会延长,查看原因?
其它 Melanoma brain metastases (BM) result in poor prognosis. Targeted therapies (TT) showed significant efficacy in monotherapy (Vemurafenib V/Dabrafenib D) and in combination (V+Cobimetinib VC/D+Trametinib DT). Encouraging data from BM treated by TT com-bination were reported. We present original results of efficacy and tol-erance in real life BM treated with TT (V/D, VC/DT) in French MelBase. It is a multicentric clinical biobank dedicated to prospective follow-up (FU) of unresectable stage III or IV melanoma adults. 1168 patients are included. Available data were collected (June 2017) and analyzed: monotherapy (gA), combination (gB). The characteristics are: gA (n = 58): mean age 58 years (48-70), PS 0-1 81%, LDH>ULN 36%, ≥3 metastatic organ sites (MOS) 60%, treated in 1st line 67%. gB (n = 64): mean age 56 years (45-64), PS 0-1 90%, LDH>ULN 39%, ≥3 MOS 63%, treated in 1st line 70%. After median FU 7.3 months (mos), median OS is 8.3 mos (95% CI:6.8-11.8;gA), 15.1 months (95% CI:7.7-NR;gB); median PFS is 4.0 mos (95% CI:3.5-5.6;gA), 6.6 mos (95% CI:5.5-8.1;gB). BORR is 31% (gA), 41% (gB); DCR is 64% (gA;gB). Age, LDH, PS, BM, radiotherapy (RT) were tested in univariate analysis. Multivariate analysis on global population (with treatment stratification) indicates that LDH (adjusted HR 1.9, 95% CI: 1.2-3.3), PS (aHR 3.6, 95% CI: 1.9-6.8), RT (aHR 2.3, 95% CI: 1.3-4.2) are significantly associated with OS; PS (aHR 3.0, 95% CI: 1.6-5.5), BM (aHR 1.5, 95% CI: 1.0-2.4) are significantly associated with PFS. OS and PFS seem similar to already published data (Davies 2017) in both groups. Adding anti-MEK increases BORR but not DCR. It increases PFS and OS but less than in patients without BM. It is the 1st study evaluating prognostic factors and pointing out RT as a good factor in multivariate analysis. Concomitant stereotaxic RT should systematically be discussed in BM patients treated by TT.
求助人
不吃早饭的猪猪子 在 2020-09-18 17:45:38 发布,悬赏 10 积分
下载
求助 / 应助时间线
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
heihei完成签到 ,获得积分20
3秒前
小二郎应助焚心绚华绘采纳,获得10
4秒前
科研通AI5应助俊逸的翠容采纳,获得10
5秒前
6秒前
7秒前
8秒前
10秒前
Oay发布了新的文献求助10
10秒前
朝天完成签到,获得积分10
11秒前
11秒前
shining完成签到,获得积分10
13秒前
14秒前
14秒前
rtaxa完成签到,获得积分0
14秒前
15秒前
16秒前
传奇3应助fishfun采纳,获得10
16秒前
17秒前
zhouleiwang发布了新的文献求助10
18秒前
18秒前
18秒前
希望天下0贩的0应助shining采纳,获得10
18秒前
花园荆棘完成签到,获得积分10
19秒前
木木发布了新的文献求助10
20秒前
彼岸花完成签到 ,获得积分10
21秒前
Grtin发布了新的文献求助10
23秒前
23秒前
超帅的遥完成签到,获得积分10
24秒前
研友_V8RmmZ发布了新的文献求助10
24秒前
26秒前
hky完成签到 ,获得积分10
29秒前
传奇3应助xxxxwjh采纳,获得10
29秒前
laber应助Peng2876649925采纳,获得30
29秒前
KristenStewart完成签到,获得积分10
30秒前
所所应助然然然后采纳,获得10
31秒前
Cl发布了新的文献求助10
32秒前
江江发布了新的文献求助20
32秒前
33秒前
科研通AI5应助dreamboat采纳,获得10
33秒前
36秒前
高分求助中
Production Logging: Theoretical and Interpretive Elements 2700
Neuromuscular and Electrodiagnostic Medicine Board Review 1000
こんなに痛いのにどうして「なんでもない」と医者にいわれてしまうのでしょうか 510
The First Nuclear Era: The Life and Times of a Technological Fixer 500
ALUMINUM STANDARDS AND DATA 500
Walter Gilbert: Selected Works 500
岡本唐貴自伝的回想画集 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 物理 生物化学 纳米技术 计算机科学 化学工程 内科学 复合材料 物理化学 电极 遗传学 量子力学 基因 冶金 催化作用
热门帖子
关注 科研通微信公众号,转发送积分 3667816
求助须知:如何正确求助?哪些是违规求助? 3226284
关于积分的说明 9768970
捐赠科研通 2936235
什么是DOI,文献DOI怎么找? 1608336
邀请新用户注册赠送积分活动 759642
科研通“疑难数据库(出版商)”最低求助积分说明 735434